title: Exercise training decreases the size and alters the composition of the neointima in a porcine model of percutaneous transluminal coronary angioplasty (PTCA).
abstract: Exercise training (EX) following percutaneous transluminal coronary angiography (PTCA) reduces progression to restenosis and increases event-free survival rates. Our aim was to determine whether EX inhibits lesion development and/or alters the extracellular matrix (ECM) composition of the neointima (NI) in a porcine PTCA model. Miniature Yucatan swine were assigned to cage confinement (SED) or EX for 20 wk. After 16 wk, all animals underwent a PTCA procedure of the left anterior descending artery (LAD) and left circumflex artery (LCX), with subsequent placement of an externalized jugular catheter. Animals recovered for 2 days and then resumed the previous protocol of SED or EX. Twelve days following PTCA, all animals received an intravenous bromodeoxyuridine (BrdU) injection to label proliferating cells. At 28 days following PTCA, the animals were euthanized, the LAD and LCX excised, and underwent standard histological processing for total collagen, type I collagen, fibronectin, BrdU, and Verhoeff-van Gieson stain. Our results demonstrate that EX significantly decreased lesion size and NI proliferation (-48%) in the LAD (P < 0.05) but not the LCX. Furthermore, EX attenuated type I collagen expression only in LAD, whereas total collagen was increased (5.9%) and fibronectin was decreased (-7.9%) in the NI of both vessels (P < 0.05). In conclusion, EX following PTCA may increase event-free survival rates following PTCA by decreasing lesion size and altering ECM composition.
authors: Department of Biomedical Sciences, University of Missouri, Columbia, Missouri 65211, USA.
authors: Bradley S
authors: BS
authors: Fleenor
authors: Douglas K
authors: DK
authors: Bowles
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D000963:Antimetabolites / Q000008:administration & dosage / Q000494:pharmacology; D001823:Body Composition / Q000187:drug effects / Q000502:physiology; D001973:Bromodeoxyuridine / Q000008:administration & dosage / Q000494:pharmacology; D049109:Cell Proliferation; D024042:Collagen Type I / Q000378:metabolism; D003331:Coronary Vessels / Q000187:drug effects / Q000502:physiology*; D016207:Cytokines / Q000378:metabolism; D005109:Extracellular Matrix / Q000502:physiology; D005353:Fibronectins / Q000378:metabolism; D007150:Immunohistochemistry; D018836:Inflammation Mediators / Q000378:metabolism; D008297:Male; D010805:Physical Conditioning, Animal / Q000502:physiology*; D013552:Swine; D013556:Swine, Miniature; D053773:Transforming Growth Factor beta1 / Q000378:metabolism
chemical_list: D000963:Antimetabolites; D024042:Collagen Type I; D016207:Cytokines; D005353:Fibronectins; D018836:Inflammation Mediators; D053773:Transforming Growth Factor beta1; D001973:Bromodeoxyuridine